Insider · CIK 0001695788
Brian Rosenberger
Files at ZYNE (Zynerba Pharmaceuticals, Inc.). First filing -, latest -.
In brief
Brian Rosenberger files SEC Form 4 as officer at ZYNE (Zynerba Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Brian Rosenberger has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 10, 2023 | ZYNE Zynerba Pharmaceuticals, Inc. | UTender of shares Common Stock | -69,559 | - | - | 180,000 | Oct 11, 2023 |
| Oct 10, 2023 | ZYNE Zynerba Pharmaceuticals, Inc. | AGrant or award Common Stock | +120,000 | - | - | 300,000 | Oct 11, 2023 |
| Oct 10, 2023 | ZYNE Zynerba Pharmaceuticals, Inc. | UTender of shares Common Stock | -300,000 | - | - | 0 | Oct 11, 2023 |
| Oct 10, 2023 | ZYNE Zynerba Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -90,000 | - | - | 0 | Oct 11, 2023 |
Questions about Brian Rosenberger
Answered from the filings on this page, as of the latest one.
Is Brian Rosenberger buying or selling?
Brian Rosenberger has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Brian Rosenberger's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian Rosenberger has 0.
Where does Brian Rosenberger file Form 4?
Brian Rosenberger has filed Form 4 at ZYNE (Zynerba Pharmaceuticals, Inc.) as VP, Commercial & Business Dev.. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.